Published in J Pharm Sci on January 01, 2004
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron (2012) 4.48
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest (2007) 3.01
STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest (2008) 2.95
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res (2006) 1.98
Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul Syst Bio (2008) 1.05
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res (2015) 0.88
Targeted TFO delivery to hepatic stellate cells. J Control Release (2011) 0.80
Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients. Theranostics (2011) 0.80
No effect on QT intervals of mipomersen, a 2'-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects. Eur J Clin Pharmacol (2015) 0.76
Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models. Mol Ther Nucleic Acids (2017) 0.75
Ca2+ enrichment in culture medium potentiates effect of oligonucleotides. Nucleic Acids Res (2015) 0.75
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med (2006) 2.74
Developing microRNA therapeutics. Circ Res (2012) 2.58
Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med (2011) 2.56
Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med (2014) 2.06
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med (2015) 2.03
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J (2011) 1.84
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J (2012) 1.79
Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem (2002) 1.57
Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos (2003) 1.57
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol (2008) 1.42
An extra quiet sun. Sci Am (2010) 1.38
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos (2006) 1.27
Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol (2013) 1.16
Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol (2011) 1.15
Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol (2012) 1.10
Developing microRNA therapeutics: approaching the unique complexities. Nucleic Acid Ther (2012) 1.10
Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides (2006) 1.09
Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals. Mutat Res (2005) 1.04
Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet (2009) 1.02
Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther (2002) 1.02
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2002) 1.01
Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis (2013) 1.00
Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys. Endocrinology (2009) 1.00
Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol (2002) 0.99
Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochem Pharmacol (2009) 0.95
Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. Am J Respir Cell Mol Biol (2006) 0.93
Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat Biotechnol (2012) 0.92
Oral delivery of antisense oligonucleotides in man. J Pharm Sci (2008) 0.91
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res (2002) 0.90
Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid. J Med Chem (2005) 0.90
Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury. Oligonucleotides (2004) 0.88
Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci (2002) 0.83
Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice. J Pharmacol Exp Ther (2007) 0.83
Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci (2004) 0.83
Renal uptake and tolerability of a 2'-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey. Toxicology (2012) 0.83
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res (2003) 0.83
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res (2002) 0.83
Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. J Thorac Oncol (2009) 0.82
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest New Drugs (2005) 0.80
CpG and Non-CpG oligodeoxynucleotides induce differential proinflammatory gene expression profiles in liver and peripheral blood leukocytes in mice. J Immunotoxicol (2006) 0.80
In vitro metabolic stabilities and metabolism of 2'-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates. Oligonucleotides (2010) 0.79
Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum. Nucleic Acid Ther (2014) 0.79
Liarozole markedly increases all trans-retinoic acid toxicity in mouse limb bud cell cultures: a model to explain the potency of the aromatic retinoid (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1-propenyl] benzoic acid. Toxicol Appl Pharmacol (2002) 0.79
Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assessments of antisense oligonucleotides. Curr Opin Drug Discov Devel (2004) 0.79
Development of an ion-pair reverse-phase liquid chromatographic/tandem mass spectrometry method for the determination of an 18-mer phosphorothioate oligonucleotide in mouse liver tissue. Eur J Mass Spectrom (Chichester, Eng) (2005) 0.78
The Oligonucleotide Safety Working Group (OSWG). Nucleic Acid Ther (2012) 0.78
Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion. Birth Defects Res B Dev Reprod Toxicol (2006) 0.76
Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimens. Antisense Nucleic Acid Drug Dev (2003) 0.76
More on science and politics. Science (2003) 0.75
Sayonara, supergiant. Sci Am (2013) 0.75
High and dry in the food desert. Sci Am (2012) 0.75
Laying odds on the apocalypse. Sci Am (2010) 0.75
More mysterious methane. Sci Am (2009) 0.75
A star's last breath: Supernova dust fell to earth in Antarctic meteorites. Sci Am (2013) 0.75
Stuff that designs itself. Self-assembling nanoparticles may be key to new materials. Sci Am (2012) 0.75
Frothy physics. Sci Am (2013) 0.75
Physics. Cloaking made simpler. Sci Am (2009) 0.75
A clinical flow cytometric biomarker strategy: validation of peripheral leukocyte phospholipidosis using Nile red. J Appl Toxicol (2006) 0.75
Damp rocks from space. Sci Am (2010) 0.75
No star left behind. What fuels a white dwarf's luminous nuclear detonation? Sci Am (2012) 0.75
Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice. Birth Defects Res B Dev Reprod Toxicol (2004) 0.75
A new wrinkle in time. Sci Am (2012) 0.75
Preventing the next Chelyabinsk. Sci Am (2013) 0.75
Shields up. Magnetized rock sets start of magnetic field closer to life. Sci Am (2010) 0.75
The last frontier. Sci Am (2012) 0.75
Monopole position. Sci Am (2009) 0.75
Filth in the spice rack. Imported seasonings are rife with all sorts of extras. Sci Am (2014) 0.75
Gender gaps. Sci Am (2013) 0.75
Assessment of the effects of ISIS 2302, an anti-sense inhibitor of human ICAM-1, on cellular and humoral immunity in mice. J Immunotoxicol (2006) 0.75
Anybody home? Sci Am (2013) 0.75
Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits. Birth Defects Res B Dev Reprod Toxicol (2004) 0.75
Buying a better bulb. Sci Am (2012) 0.75
Hawking was right (probably). Researchers may have re-created an elusive black hole phenomenon in the lab. Sci Am (2010) 0.75
Nobel pursuits: The tools of science have changed since the golden age of physics, but many of the same questions remain. Sci Am (2012) 0.75
Does infinity come in different sizes? Sci Am (2008) 0.75
Not set in stone (or ice). Sci Am (2009) 0.75
12 events that will change everything. Sci Am (2010) 0.75
Tag--you're sick: patterns of personal contact in a hospital reveal true pathways of transmission. Sci Am (2012) 0.75
Space age wasteland. Debris in orbit is here to stay. Sci Am (2012) 0.75
Feeling the heat. Sci Am (2011) 0.75
Lunar pencil lead. Sci Am (2010) 0.75
Swimming on Mars. The Red Planet may have once been home to an ocean. Sci Am (2012) 0.75
Closer to home. Sci Am (2013) 0.75
Mission: risk-averse. Sci Am (2013) 0.75
Renewable energy's hidden costs. Sci Am (2013) 0.75
You are here. Sci Am (2012) 0.75
The dwindling web. Sci Am (2012) 0.75
Tensions over taikonauts. Sci Am (2012) 0.75
Fire and water. Sci Am (2012) 0.75
Planets Everywhere. Systematic searches are revealing a plenitude of alien worlds. Sci Am (2012) 0.75
On the trail of space trash. Sci Am (2011) 0.75